Cover Kidney News
Volume/Issue:
Volume 12: Issue 2
Page:
13
Publication Date:
01 Feb 2020
Online Publication Date:
06 Feb 2020
  • 1.

    Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380:2295–2306.

  • 2.

    Heerspink HJL, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double-blind, randomised, placebo-controlled trial. Lancet 2019; 393:1937–1947.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Mann JF, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21:527–535.

  • 4.

    Trachtman H, et al. DUET: A phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol 2018; 29:2745–2754.

Editorial Type:
Features

Endothelin Receptor Antagonism in CKD: SONAR and Beyond

Donald KohanDonald Kohan, MD, PhD, is DRF Endowed Chair in Nephrology, and professor of medicine at the University of Utah Health Center in Salt Lake City.

Search for other papers by Donald Kohan in
Current site
Google Scholar
PubMedClose
Volume/Issue:
Volume 12: Issue 2
Publication Date:
01 Feb 2020
Page:
13
Restricted access
Save